Literature DB >> 19026465

Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006.

Jo-David Fine1, Lorraine B Johnson, Madeline Weiner, Kuo-Ping Li, Chirayath Suchindran.   

Abstract

BACKGROUND: Case series have demonstrated that potentially lethal cutaneous squamous cell carcinomas arise in patients with recessive dystrophic epidermolysis bullosa (RDEB), although the magnitude of this risk is undefined.
METHODS: Systematic case finding and data collection were performed throughout the continental United States (1986-2002) by the National EB Registry on 3280 EB patients to determine cumulative and conditional risks for squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and malignant melanoma (MM) within each major EB subtype, as well as the cumulative risk of death from each tumor. Study design was cross-sectional, with a nested randomly sampled longitudinal subcohort (N = 450).
RESULTS: SCCs arose primarily in RDEB, especially the Hallopeau-Siemens subtype (RDEB-HS), first beginning in adolescence. Less frequently, SCCs occurred in junctional EB (JEB). Cumulative risks rose steeply in RDEB-HS, from 7.5% by age 20 to 67.8%, 80.2%, and 90.1% by ages 35, 45, and 55, respectively. In Herlitz JEB, the risk was 18.2% by age 25. SCC deaths occurred only in RDEB, with cumulative risks in RDEB-HS of 38.7%, 70.0%, and 78.7% by ages 35, 45, and 55, respectively. MM arose in RDEB-HS, with a cumulative risk of 2.5% by age 12. BCCs arose almost exclusively in the most severe EB simplex subtype (Dowling-Meara) (cumulative risk = 43.6% by age 55). LIMITATIONS: Mutational analyses were performed on only a minority of enrollees in the National EB Registry, preventing evaluation of the possible influence of specific genotypes on the risk of developing or dying from cutaneous SCCs.
CONCLUSIONS: SCC is the most serious complication of EB within adults, especially those with RDEB-HS. By mid-adulthood, nearly all will have had at least one SCC, and nearly 80% will have died of metastatic SCC despite aggressive surgical resection. When compared with SCCs arising within the normal population, the remarkably high risk of occurrence of and then death from SCCs among RDEB patients suggests likely differences in pathogenesis. Additional studies of EB-derived tumors and SCC cell lines may not only provide new insights into the mechanisms of carcinogenesis but also means whereby these particular tumors may be prevented or more effectively treated.

Entities:  

Mesh:

Year:  2008        PMID: 19026465     DOI: 10.1016/j.jaad.2008.09.035

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  84 in total

1.  Management of high-risk cutaneous squamous cell carcinoma.

Authors:  Lorraine Jennings; Chrysalyne D Schmults
Journal:  J Clin Aesthet Dermatol       Date:  2010-04

Review 2.  The collagenopathies: review of clinical phenotypes and molecular correlations.

Authors:  Rebekah Jobling; Rohan D'Souza; Naomi Baker; Irene Lara-Corrales; Roberto Mendoza-Londono; Lucie Dupuis; Ravi Savarirayan; L Ala-Kokko; Peter Kannu
Journal:  Curr Rheumatol Rep       Date:  2014-01       Impact factor: 4.592

Review 3.  [Epidermolysis bullosa. An update].

Authors:  H Schumann
Journal:  Hautarzt       Date:  2009-08       Impact factor: 0.751

4.  Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa.

Authors:  Alexander Nyström; Olivier Bornert; Tobias Kühl; Christine Gretzmeier; Kerstin Thriene; Jörn Dengjel; Andrea Pfister-Wartha; Dimitra Kiritsi; Leena Bruckner-Tuderman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-05       Impact factor: 11.205

5.  Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity.

Authors:  Johannes S Kern; Stefan Loeckermann; Anja Fritsch; Ingrid Hausser; Wera Roth; Thomas M Magin; Claudia Mack; Marcel L Müller; Oliver Paul; Patrick Ruther; Leena Bruckner-Tuderman
Journal:  Mol Ther       Date:  2009-06-30       Impact factor: 11.454

6.  Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa.

Authors:  Su M Lwin; Farhatullah Syed; Wei-Li Di; Tendai Kadiyirire; Lu Liu; Alyson Guy; Anastasia Petrova; Alya Abdul-Wahab; Fiona Reid; Rachel Phillips; Maria Elstad; Christos Georgiadis; Sophia Aristodemou; Patricia A Lovell; James R McMillan; John Mee; Snaigune Miskinyte; Matthias Titeux; Linda Ozoemena; Rashida Pramanik; Sonia Serrano; Racheal Rowles; Clarisse Maurin; Elizabeth Orrin; Magdalena Martinez-Queipo; Ellie Rashidghamat; Christos Tziotzios; Alexandros Onoufriadis; Mei Chen; Lucas Chan; Farzin Farzaneh; Marcela Del Rio; Jakub Tolar; Johann W Bauer; Fernando Larcher; Michael N Antoniou; Alain Hovnanian; Adrian J Thrasher; Jemima E Mellerio; Waseem Qasim; John A McGrath
Journal:  JCI Insight       Date:  2019-06-06

7.  A consensus approach to wound care in epidermolysis bullosa.

Authors:  Elena Pope; Irene Lara-Corrales; Jemima Mellerio; Anna Martinez; Gregory Schultz; Robert Burrell; Laurie Goodman; Patricia Coutts; John Wagner; Upton Allen; Gary Sibbald
Journal:  J Am Acad Dermatol       Date:  2012-03-02       Impact factor: 11.527

8.  [Parallels between wound healing, chronic inflammatory skin diseases and neoplasia: clinical aspects].

Authors:  A Brown; I Tantcheva-Poor; S A Eming
Journal:  Hautarzt       Date:  2014-11       Impact factor: 0.751

Review 9.  Inherited epidermolysis bullosa.

Authors:  Jo-David Fine
Journal:  Orphanet J Rare Dis       Date:  2010-05-28       Impact factor: 4.123

Review 10.  Oral manifestations in the epidermolysis bullosa spectrum.

Authors:  J Timothy Wright
Journal:  Dermatol Clin       Date:  2010-01       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.